Rhys Whomsley

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

The in vitro alkaline comet assay with liver models as a complementary tool for genotoxicity assessment of N-nitrosamines.

The in vitro alkaline comet assay with liver models as a complementary tool for genotoxicity assessment of N-nitrosamines.

Journal: Archives of toxicology

Published: March 26, 2026

A framework to Identify High-Priority Legacy Active Pharmaceutical Ingredients for Environmental Risk Assessment.

A framework to Identify High-Priority Legacy Active Pharmaceutical Ingredients for Environmental Risk Assessment.

Journal: Integrated environmental assessment and management

Published: January 13, 2026

Nitrosamine drug substance-related impurities cause DNA methylation adducts in vitro and in primary hepatocytes upon Cytochrome P450-dependend metabolic activation.

Nitrosamine drug substance-related impurities cause DNA methylation adducts in vitro and in primary hepatocytes upon Cytochrome P450-dependend metabolic activation.

Journal: Regulatory toxicology and pharmacology : RTP

Published: November 04, 2025

Nitrosamine Ames Data Review and Method Development: proceedings of a US FDA/HESI workshop.

Nitrosamine Ames Data Review and Method Development: proceedings of a US FDA/HESI workshop.

Journal: Mutagenesis

Published: September 11, 2025

Estimation of bioavailable concentration of endogenously formed N-nitrosamines by physiologically based kinetic modelling.

Estimation of bioavailable concentration of endogenously formed N-nitrosamines by physiologically based kinetic modelling.

Journal: ALTEX

Published: December 06, 2024

Quantitative Investigation of Nitrosamine Drug Substance-Related Impurities (NDSRIs) Under Artificial Gastric Conditions by Liquid Chromatography-Tandem Mass Spectrometry and Structure-Activity Relationship Analysis.

Quantitative Investigation of Nitrosamine Drug Substance-Related Impurities (NDSRIs) Under Artificial Gastric Conditions by Liquid Chromatography-Tandem Mass Spectrometry and Structure-Activity Relationship Analysis.

Journal: Drug testing and analysis

Published: July 25, 2024

Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).

Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).

Journal: Regulatory toxicology and pharmacology : RTP

Published: April 22, 2024

Prioritisation of data-poor pharmaceuticals for empirical testing and environmental risk assessment.

Prioritisation of data-poor pharmaceuticals for empirical testing and environmental risk assessment.

Journal: Environment international

Published: August 21, 2023

EMA commentary on the ICH guideline for testing for carcinogenicity of pharmaceuticals.

EMA commentary on the ICH guideline for testing for carcinogenicity of pharmaceuticals.

Journal: British journal of clinical pharmacology

Published: April 20, 2023

The EU Response to the Presence of Nitrosamine Impurities in Medicines.

The EU Response to the Presence of Nitrosamine Impurities in Medicines.

Journal: Frontiers in medicine

Published: September 24, 2021

Environmental risk assessment of advanced therapies containing genetically modified organisms in the EU.

Environmental risk assessment of advanced therapies containing genetically modified organisms in the EU.

Journal: British journal of clinical pharmacology

Published: June 18, 2020

Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver Cancer.

Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver Cancer.

Journal: Radiology

Published: October 17, 2019

Showing 1-12 of 13

Last Updated: 09/26/2026